Royalty Sales & Financings

Representative Matters

• Advising Northwestern University in connection with the sale of a portion of its worldwide royalty interest in Lyrica for $700 million, the largest monetization ever of a royalty stream for a pharmaceutical product.
• Advising Emory University in connection with its ground-breaking monetization of the royalty rights associated with Emtriva for $540 million, recognized by Investment Dealers’ Digest as the 2005 Healthcare Deal of the Year.
• Advising a major university in connection with the potential monetization of royalty rights associated with certain vaccines and diagnostic products.
• Advising a leading health care company with respect to the sale of a pharmaceutical royalty stream from a global manufacturer of health care products.
• Advising a leading pharmaceutical company with respect to a proposed acquisition of a minority interest in a pharmaceutical royalty stream from a biopharmaceutical company.
• Advising a group of inventors of a pharmaceutical compound with respect to a monetization of its rights to payments received by a major university as a result of the successful licensing (and sublicensing) of the compound.
• Assisting Centre Solutions, a member of the Zurich Financial Services Group, with developing and structuring the first pharmaceutical royalty securitization, a $130 million senior/subordinated financing, on behalf of a major university, of the rights associated with the intellectual property at the core of a blockbuster pharmaceutical product.
• Advising Centre Solutions with respect to two other financings of, and purchases of equity rights associated with, two different portfolios of specific pharmaceutical royalty streams.
• Advising Centre Solutions in connection with a sale of its interest in a pharmaceutical royalty stream to a leading royalty financier.
• Advising an investment fund in connection with a proposed acquisition of a pharmaceutical royalty stream.
• Advising a major UK bank in its $175 million structured financing of certain rights associated with various pharmaceutical products owned by a leading pharmaceutical company.
• Advising a leading Dutch financial institution, as agent, in a $180 million structured financing of certain intellectual property rights associated with pharmaceutical products owned by a leading life sciences company.